Abstract
BRAFV600E mutation has been thought to be a valuable molecular marker that may predict a worse prognosis for papillary thyroid cancer (PTC). But whether BRAFV600E mutation is associated with lymph node metastasis (LNM) remains controversial. Different surgical strategies may bring a bias in demonsstrating the association between them. In order to delineate a risk stratification to guide a tailored initial approach to tumors that express BRAFV600E mutation, we performed this meta-analysis by using the articles in which total or near-total thyroidectomy plus bilateral central lymph node dissection was routinely performed to avoid the bias from the surgical strategy. We searched the Medline, Embase and CNKI database for eligible studies from January 2003 to May 2018. Meta-analysis was performed using the STATA 12.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed-effects or randomeffects models. Fifteen clinical studies were included with a total of 4909 PTC patients. Our meta-analysis results reported that BRAFV600E mutation was associated with LNM (OR=1.34; 95% CI: 1.09–1.65; P=0.005), as well as central LNM (OR=1.59; 95% CI: 1.35–1.88; P<0.00001). Moreover, in patients with papillary thyroid microcarcinoma, we also confirmed the predictive value of BRAFV600E mutation for LNM (OR=3.49; 95% CI: 2.02–6.02; P<0.00001). This meta-analysis demonstrates that BRAFV600E mutation is closely related to LNM in PTC patients. The results suggest that BRAFV600E mutation can be considered as a risk factor for LNM in PTC. Moreover, combining BRAFV600E mutation with other risk factors to determine the initial surgical treatment may bring benefits for PTC patients.
Similar content being viewed by others
References
Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013,2013:965212
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 2006,295(18):2164–2167
Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U. S., 1985–1995 [see commetns]. Cancer, 1998,83(12):2638–2648
Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab, 1997,82(11):3553–3562
Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U. S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer, 2000,89(1):202–217
Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw, 2005,3(3):404–457
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994,97(5):418–428
Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 2003,88(11):5399–5404
Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J, 2004,45(5):818–821
Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005,90(12):6373–6379
Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg, 2006,244(5):799–804
Nakayama H, Yoshida A, Nakamura Y, et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res, 2007,27(5B):3645–3649
Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007,246(3):466–470; discussion 470–461
Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007,92(11):4085–4090
Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer, 2007,110(6):1218–1226
Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008,15(1):191–205
Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 2009,94(5):1612–1617
Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol, 2009,16(2):240–245
Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer, 2009,115(5):972–980
Gong RX, Zhou Y, Luo SH, et al. An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (Chinese), 2009,26(3):310–313
Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab, 2010,95(9):4197–4205
Sykorova V, Dvorakova S, Ryska A, et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest, 2010,33(5):318–324
So YK, Son YI, Park JY, et al. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg, 2011,145(3):422–427
Junfeng LU, Xie N, Yinan JI. The Correlation between BRAFV600E Gene Mutation and p27 Expression and Lymph Node Metastasis of Papillary Thyroid Carcinoma. Hebei Yixue (Chinese), 2011,17:711–714
Lee JI, Jang HW, Kim SW, et al. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck, 2013,35(4):548–553
Gao WL, Wie LL, Chao YG, et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab, 2012,58(9–10):919–926
Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol, 2012,23(2):83–93
Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab, 2012,97(7):2333–2340
Joo JY, Park JY, Yoon YH, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab, 2012,97(11):3996–4003
Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 2012,36(2):310–317
Kurtulmus N, Duren M, Ince U, et al. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine, 2012,42(2):404–410
Zheng X, Xia T, Lin L, et al. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol, 2012,10:104
Zhao HT, Zhao CQ, Zhang B. Expression and significance of CD44v6, BRAF and Rasp21 in papillary thyroid carcinoma. Zhongguo Zhongliu Linchuang Yu Kangfu (Chinese), 2012,19(4):310–312
Yi W, Zhong D, Zou Q. BRAF mutation and papillary thyroid cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2012,37(4):370–373
Alzahrani AS, Xing M. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer, 2013,20(1):13–22
Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013,139(11):1164–1170
Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 2013,20(1):47–52
Jeong D, Jeong Y, Park JH, et al. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol, 2013,20(3):759–766
Li C, Aragon Han P, Lee KC, et al. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab, 2013,98(9):3702–3712
Rossi ED, Martini M, Capodimonti S, et al. BRAF (V600E) mutation analysis on liquid-based cytologyprocessed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol, 2013,121(6):291–297
Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol, 2013,20(7):2266–2273
Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid, 2013,23(11):1423–1430
Pu YB. Clinical significance of BRAFV600E in papillary thyroid cancer. Shiyong Aizheng Zazhi (Chinese), 2013,28(3):246–248
Jiang X, Xie N. Expression and significance of the BRAFV600E-mutated Protein in papillary thyroid carcinoma. Guangdong Yixue (Chinese), 2013,34:931–933
Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg, 2015,262(3):519–525; discussion 524–515
Bastos AU, Oler G, Nozima BH, et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol, 2015,173(4):525–540
Kim SK, Woo JW, Lee JH, et al. Role of BRAFV600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery, 2015,158(6):1500–1511
Shi CL, Sun Y, Ding C, et al. Correlation between the BRAFV600E mutation status and the clinicopathologic features of papillary thyroid carcinoma. Genet Mol Res, 2015,14(3):7377–7385
Fraser S, Go C, Aniss A, et al. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg, 2016,40(7):1618–1624
Qu HJ, Qu XY, Hu Z, et al. The synergic effect of BRAF(V600E) mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma. Endocr J, 2018,65(1):113–120
Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003,88(9):4393–4397
Yin XL, Zhang GC, Feng LI, et al. BRAFV600E Mutation in Papillary Thyroid Cancer by MASAPCR. Shihezi Daxue Xuebao (Ziran Kexue Ban), 2005,23:552–554
Zhu XL, Zhou XY, Zhu XZ. BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma. Zhonghua Bing Li Xue Za Zhi (Chinese), 2005,34(5):270–274
Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf), 2005,63(5):588–593
Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf), 2005,63(4):461–466
Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 2006,30(2):216–222
Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer, 2006,13(2):455–464
Jo YS, Li S, Song JH, et al. Influence of the BRAFV600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab, 2006,91(9):3667–3670
Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2006,65(3):364–368
Lee JH, Lee ES, Kim YS, et al. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology, 2006,38(3):201–204
Abrosimov A, Saenko V, Rogounovitch T, et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer, 2007,120(1):196–200
Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2008,68(4):618–634
Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008,93(10):3943–3949
Niu W, Luo YQ, Chen LR. Clinical significance of BRAF mutation and expression in papillary thyroid carcinoma. Journal of Practical Oncology, 2008,23(6):519–523
Mi Z, Wang A, Zhao Z, et al. Study of BRAFV600E mutation in papillary thyroid cancer. Shaanxi Med J (Chinese), 2008,37:1471–1477
Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J, 2009,56(1):89–97
Kwak JY, Kim EK, Chung WY, et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology, 2009,253(3):854–860
Zang X, Chen J, Lin H, et al. The research of BRAFV600E mutation in papillary thyroid cancer. Xiandai Shiyong Yixue (Chinese), 2009,21:1296-1297
Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010,17(12):3294–3300
Stanojevic B, Dzodic R, Saenko V, et al. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J, 2011,58(5):381–393
Eloy C, Santos J, Soares P, et al. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch, 2011,459(3):265–276
Pelizzo MR, Boschin IM, Barollo S, et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med, 2011,49(2):325–329
Zheng X, Xia T, Lin L, et al. BRAFV600E Mutational Status and Ciinico-biological Characteristics of Multifocal Papillary Thyroid Carcinomas. Zhongguo Zhongliu Linchuang (Chinese), 2011,38:1326–1329
Dai Y, Li B, Wang S. The association between BRAF mutation and lymph node metastasis in papillary thyroid cancer. Zhongguo Yixue Chuangxin (Chinese), 2011,8(31):29–30
Paulson L, Shindo M, Schuff K, et al. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg, 2012,138(1):44–49
Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600Emutated protein in papillary thyroid carcinoma. Am J Surg Pathol, 2012,36(6):844–850
Ahn D, Park JS, Sohn JH, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx, 2012,39(2):198–203
Kurt B, Yalcin S, Alagoz E, et al. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol, 2012,23(3):135–140
Lee KC, Li C, Schneider EB, et al. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery, 2012,152(6):977–983
Lee ST, Kim SW, Ki CS, et al. Clinical implication of highly sensitive detection of the BRAFV600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab, 2012,97(7):2299–2306
Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg, 2012,203(4):436–441
Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid, 2012,22(1):17–26
Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with diseasefree interval. Clin Endocrinol (Oxf), 2012,77(5):780–786
Xiao-Qiang LI, Zhang HZ, Jiang ZM, et al. Expression of BRAF gene and its significance in papillary thyroid carcinoma. J Clin Exp Pathol, 2012,28:991–995
Xia T, Chuanxiang HU, Zhao J, et al. BRAFV600E Mutation in Papillary Thyroid Carcinoma. Chin J Clin Oncol (Chinese), 2012,7(2):439–443(435)
Kim YS, Kim JS, Bae JS, et al. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol, 2013,11:99
Fernandez IJ, Piccin O, Sciascia S, et al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg, 2013,148(6):919–925
Gandolfi G, Sancisi V, Torricelli F, et al. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab, 2013,98(5):E934–E942
McKelvie PA, Chan F, Yu Y, et al. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology, 2013,45(7):637–644
Choi SY, Park H, Kang MK, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013,11:291
Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery, 2013,154(6):1199–1204; discussion 1204–1195
Gong Y, Gong R, Yang J, et al. The association between BRAF mutation and clinicopathological characteristics and its clinical implication in papillary thyroid cancer. Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese), 2013,44:662–665
Zheng L, Hu X. Significance of expressions of HBME-1, Galectin-3, CK19 and BRAF mutation in papillary thyroid carcinoma. Anhui Yike Daxue Xuebao (Chinese), 2013,48(4):401–405
Danilovic DL, Lima EU, Domingues RB, et al. Preoperative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol, 2014,170(4):619–625
Walczyk A, Kowalska A, Kowalik A, et al. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf), 2014,80(6):899–904
Walts AE, Mirocha JM, Bose S. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. J Cancer Res Clin Oncol, 2015,141(10):1749–1756
Park VY, Kim EK, Lee HS, et al. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study. Medicine (Baltimore), 2015,94(28):e1149
Czarniecka A, Kowal M, Rusinek D, et al. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One, 2015,10(7):e0132821
Lin JD, Fu SS, Chen JY, et al. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene. Thyroid, 2016,26(5):691–704
Sun J, Zhang J, Lu J, et al. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One, 2016,11(4):e0153319
Park VY, Kim EK, Moon HJ, et al. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC. Medicine (Baltimore), 2016,95(29):e4292
Fakhruddin N, Jabbour M, Novy M, et al. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Sci Rep, 2017,7(1):4666
Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore), 2012,91(5):274–286
Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 2012,118(7):1764–1773
Zhang Q, Liu SZ, Zhang Q, et al. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem, 2016,38(2):763–776
Ma B, Wang Y, Yang S, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis. Int J Surg, 2016,28:153–161
Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a metaanalysis. World J Surg Oncol, 2016,14(1):241
Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer, 2007,110(1):38–46
Zimmermann AK, Camenisch U, Rechsteiner MP, et al. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol, 2014,122(1):48–58
Fisher KE, Neill SG, Ehsani L, et al. Immunohistochemical investigation of BRAF p. V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. Appl Immunohistochem Mol Morphol, 2014,22(8):562–567
Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg, 2006,141(5):489–494; discussion 494–486
Vergez S, Sarini J, Percodani J, et al. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol, 2010,36(8):777–782
Conzo G, Pasquali D, Bellastella G, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine, 2013,44(2):419–425
Barczynski M, Konturek A, Stopa M, et al. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg, 2013,100(3):410–418
Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope, 2009,119(6):1135–1139
Glover AR, Gundara JS, Norlen O, et al. The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. Gland Surg, 2013,2(4):196–205
Rosenbaum MA, McHenry CR. Central neck dissection for papillary thyroid cancer. Arch Otolaryngol Head Neck Surg, 2009,135(11):1092–1097
Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg, 2011,254(4):653–660
Ward LS, Morari EC, Leite JL, et al. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol, 2007,51(5):713–722
Zhou YL, Zhang W, Gao EL, et al. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev, 2012,13(4):1267–1272
Author information
Authors and Affiliations
Corresponding authors
Additional information
This study was supported by National Natural Science Foundation of China (No. 81702650), Natural Science Foundation of Hubei Province (No. 2016CFB323) and Innovation Foundation of Huazhong University of Science and Technology (No. 2016YXMS229).
Rights and permissions
About this article
Cite this article
Song, Jy., Sun, Sr., Dong, F. et al. Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis. CURR MED SCI 38, 785–797 (2018). https://doi.org/10.1007/s11596-018-1945-7
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-018-1945-7